Roche unveils data for Kadcyla move into early breast cancer by Eric Sagonowsky Wednesday, December 5, 2018 With biosim rivals looming, Roche will need its newer meds to step up, and Wednesday's Kadcyla data could give its breast cancer franchise a boost.
Roche insists its new drugs will outgrow U.S. biosim erosion by Angus Liu Wednesday, October 17, 2018 Roche’s blockbuster cancer trio held their ground so far this year despite biosimilar rivals in the EU, thanks to growth in the U.S. and China.
Can new Kadcyla data soften the blow when Herceptin biosims hit? by Tracy Staton Monday, October 15, 2018 Roche is teeing up a new use for its breast cancer drug Kadcyla, hoping to gin up sales as Herceptin biosimilars hurtle toward the U.S. market.
NICE stands firm on 'no' vote for Roche's Perjeta by Carly Helfand Monday, August 20, 2018 Back in June, England’s cost watchdog refused to recommend Roche’s Perjeta for postsurgery breast cancer patients. And it’s sticking by that decision.
Ocrevus, Roche's 'most successful launch,' crosses blockbuster line by Angus Liu Thursday, July 26, 2018 Roche's first-half sales climbed 7% to $28.3 billion, their fastest clip in about three years, thanks to stepped-up performance from its newer drugs.
Roche halts 2018 price hikes, with 2 rounds already on the books by Angus Liu Monday, July 23, 2018 Roche in July boosted the prices of nine medicines by an average of about 3%, including blockbuster oncology drugs Herceptin, Avastin and Rituxan.
NICE dogs Roche's Perjeta again by Carly Helfand Friday, June 15, 2018 England’s cost watchdogs are blocking reimbursement of Roche's Perjeta for some postsurgery patients with early breast cancer.
Roche snags another Perjeta nod, but will 'weak' data limit use? by Carly Helfand Wednesday, December 27, 2017 Analysts and investors think Perjeta’s end-of-the-year indication may not be as lucrative as they once hoped.
